StreetAlpha.app
Home › Stocks › RZLT

Rezolute, Inc. (RZLT)

Healthcare
$4.01
▲ +12.15%
LAST CLOSE · NOV 17

Rezolute is a Redwood City pharmaceutical company developing ersodetug to treat low blood sugar caused by hyperinsulinism. It last closed at $4.01 on Nov 17, up 12.15% on the day. RZLT reports earnings on Thu, Feb 11, 2027. The average 12-month price target from 5 analysts is $10.80 (+169.0% from the last close), with a high of $15.00 and a low of $7.00. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell).

AI Auto Pilots
Is RZLT in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$77.9M
EPS (diluted)
−$0.75
Valuation
Market cap
$388.4M
96.7M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$8.2M
At Sep 30
Shareholder equity
$85.9M
Shares outstanding
96.7M
At Nov 2
Fiscal year endsJune
ExchangeNasdaq
Financials history
FY2022: −$41.1M−$41.1MFY2022FY2023: −$51.8M−$51.8MFY2023FY2024: −$68.5M−$68.5MFY2024FY2025: −$74.4M−$74.4MFY2025FY2026: −$77.6M−$77.6MFY2026

From RZLT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Feb 11
2027 · Time not announced
Consensus EPS forecast
-$0.17
$1.2M revenue est.
Year-ago EPS
-$0.22
Same quarter last year
Options-implied move
—
Posted about a week before
Analyst consensus
Strong Buy
Based on 5 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
5firms
5 Buy0 Hold0 Sell
Each firm's latest rating on RZLT in the past 90 days
Average 12-month target
$10.80
▲ 169.0% upside

Based on 5 analysts who set a price target on RZLT in the past 90 days. The average target is $10.80, with a high of $15.00 and a low of $7.00, compared with the last close of $4.01.

Low $7.00Avg $10.80High $15.00
Blue marker: last close $4.01
Highest target$15.00
Average target$10.80
Lowest target$7.00
Latest rating changes
WedbushTarget raised
Nov 17Buy$6 → $10
Lake StreetTarget raised
Oct 6Buy$9 → $12
CitizensTarget raised
Oct 6Buy$11 → $15
Lake StreetInitiated
Sep 30Buy$9
Craig-HallumUpgrade
Sep 29Buy$7
DateFirmActionRatingPrice target
Nov 17WedbushTarget raisedBuy$6 → $10
Oct 6Lake StreetTarget raisedBuy$9 → $12
Oct 6CitizensTarget raisedBuy$11 → $15
Sep 30Lake StreetInitiatedBuy$9
Sep 29Craig-HallumUpgradeBuy$7
Loading…

Technical Analysis

RZLT · as of the Nov 17 close · updated after every close
Moving sideways

The stock sits between its 20 and 50 day averages. It is 2% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 51). The nearest support is the swing low (Sep 10) at $3.97, and the nearest resistance the 50 day average at $4.04.

Short trendNeutral
Long trendBullish
MomentumImproving
StretchNormal
VolatilityHigh, 9.0%/day
Key levels
$11.1752 week high+178.6%
$4.42100 day average+10.2%
$4.32Swing high (Nov 4)+7.7%
$4.21Pivot R1+5.0%
$4.0450 day average+0.7%
$4.01Last close
$3.97Swing low (Sep 10)−1.0%
$3.93200 day average−2.0%
$3.9020 day average−2.7%
$3.84Pivot−4.2%
$3.64Pivot S1−9.2%
$1.0752 week low−73.3%
Indicators
RSI (14)51.36Middle of its rangeNeutral
MACD-0.08Below its signal lineBearish
Stochastic26.0Middle of its rangeNeutral
ADX (14)12.4No clear trend
Williams %R-47.8Oversold below −80, overbought above −20Neutral
CCI (20)-41.2Oversold below −100, overbought above 100Neutral
Rate of change+0.1%Change over 10 sessionsBullish
ATR (14)$0.36Typical daily range, 9.1% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Above
What happened before, for RZLT

What happened before

See how RZLT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow RZLT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How RZLT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in RZLT in the last 90 days.

Loading…

See today’s whale options flow across the market →

RZLT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼60 buying vs 76 selling
  • ▼Held by funds -1.9 pts
  • ▼Funds holding -10
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding136146−6.8%
In funds' top 1002−100.0%
Held by funds87.8%89.6%−1.9 pts
New / increased18 / 4239 / 60−39.4%
Reduced / sold out49 / 2730 / 19+55.1%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RZLT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RZLT is in one of them and how their past RZLT trades turned out.

RZLT in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RZLT in an article yet. Here's the latest on the wider market.

About Rezolute

Rezolute is a pharmaceutical company based in Redwood City, California, that is developing treatments for hypoglycemia, or dangerously low blood sugar, caused by hyperinsulinism. Its main candidate, ersodetug, is an intravenously given antibody that acts on the insulin receptor to help bring blood glucose back into a more normal range. The company is studying the drug in children with congenital hyperinsulinism and in patients with tumor-related hyperinsulinism. Its work is aimed at patients and families affected by these rare conditions, for whom current treatment options are limited.

Headquarters
Redwood City, CA